Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
Olaparib + Pembrolizumab for Melanoma
Recruiting3 awardsPhase 2
San Francisco, California
This trial tests a combination of olaparib and pembrolizumab in patients with advanced melanoma who have specific genetic mutations. Olaparib blocks cancer cell growth by interfering with DNA repair, while pembrolizumab boosts the immune system to fight cancer. The goal is to see if this combination works better for patients who haven't responded to other treatments.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service